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Background: This article describes a tentative diagnostic algorithm for investigating patients with 
unexpected prolongation of activated partial thromboplastin time (APTT), detected during preoperative 
laboratory testing. 
Methods: The study population consisted of all patients undergoing preoperative laboratory testing (thus 
including APTT) during a 3-month period. Whenever prolonged APTT results were observed, abnormal 
data were investigated according to an algorithm combining familiar history of bleeding (yes/no), personal 
history of bleeding (yes/no) and signs/symptoms of bleeding with results of hemostasis testing, including 
mixing test, lupus anticoagulant (LAC) and clotting factor assays.
Results: Overall, 1,433 patients underwent preoperative APTT testing throughout the 3-month study 
period, 76 (5.3%) of whom had prolonged values (i.e., >36.5 s). The remaining 1,357 (94.7%) patients 
underwent successful surgery, without further investigation. According to the algorithm, 55/76 (72.4%) 
of patients with prolonged APTT were excluded from supplementary laboratory testing. In the remaining 
21/76 (27.6%) patients, a mixing test was scheduled. In 5/21 (23.8%) of these patients the mixing test was 
positive (i.e., no normalization), so that LAC testing was planned. In all these five patients LAC testing was 
positive. In the remaining 16/21 (76.2%) patients, mixing test was negative (i.e., normalization), so that 
clotting factors assays were scheduled. Seven patients were finally diagnosed with factor (F)XII deficiency, 
two patients with mild FXI deficiency (i.e., FXI activity of 47% and 51%), whilst 5 had clinically insignificant 
decreased values of one or more clotting factors and 2 patients had no identifiable explanation for APTT 
prolongation. The sensitivity and specificity of the algorithm for detecting clinically significant conditions 
(i.e., FXI deficiencies or LAC) were 1.00 and 0.99, respectively.
Conclusions: The results of this study suggest that a preoperative algorithm including clinical and 
laboratory data may be a reasonable and sustainable approach for identifying patients at enhanced risk of 
perioperative bleeding or thrombosis.
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Introduction
There is now consolidated evidence that results of 
laboratory testing are integral to the clinical decision 
making (1). Although this concept is straightforward and 
legitimate in virtually all branches of modern medicine, 
it hires an even greater significance for patients with 
bleeding disorders, wherein an accurate and discretionary 
use of laboratory resources accomplishes an unreplaceable 
diagnostic value (2,3).
Preoperative laboratory testing is conventionally defined 
as performing a panel of laboratory analyses aimed at 
predicting the risk of perioperative complications, defining 
the status of coexisting disorders, and detecting unidentified 
factors or conditions which may ultimately enhance the 
risk of adverse events (4). Albeit there is still open debate 
on the number and type of laboratory analyses that shall be 
included within preoperative test menus (5), the activated 
partial thromboplastin time (APTT) is frequently part of 
these panels (6), since it may help identifying a number 
of possible underlying hemorrhagic conditions that 
may expose the patient to a significantly enhanced risk 
of perioperative bleeding, or may else provide valuable 
information on the presence of prothrombotic conditions 
necessitating specific prophylaxis and tailored postsurgical 
management. Whilst significant APTT prolongations may 
hence be frequently encountered in patients with congenital 
or acquired deficiencies of clotting factors of the formerly 
known “intrinsic pathway” [i.e., prekallikrein, kininogen, 
factor (F) VIII, IX, XI and XII], or with inherited or 
acquired inhibitors against clotting factors (e.g., acquired 
haemophilia), abnormal values may also be found when 
analyzing unsuitable plasma samples, as well as in patients 
with lupus anticoagulant (LAC) or in treatment with 
anticoagulant drugs (i.e., heparin, warfarin or direct oral 
anticoagulants) (7,8). The evidence that some of these 
conditions are not clear causes of significant perioperative 
bleeding (e.g., factor FXII deficiency, LAC), but their 
association with prolonged APTT encountered during 
preoperative testing may possibly lead to delaying surgical 
procedure or, in the worst scenario, to the inappropriate 
administration of replacement therapy, has contributed 
to raise doubts as to whether including APTT within 
preoperative test panels may cause more harms then 
benefits (9-11). 
Test ordering according to the Bayesian principle of pre-
test probability (12), thus entailing an accurate collection 
of preoperative clinical history and physical examination, 
seems the most reasonable strategy not only for optimizing 
resources (both economic and human) in the laboratory, 
but also for preventing harm and inconvenience to the 
patients (13). This article is hence aimed to validate a 
tentative diagnostic algorithm for investigating patients 
with unexpected prolongation of APTT, detected during 
preoperative laboratory testing, and combining clinical and 
laboratory data.
Methods
The study population consisted of all patients undergoing 
preoperative laboratory testing (thus including APTT) 
at the Istituto Fiorentino Cura e Assistenza (IFCA, 
Florence, Italy) before undergoing surgical procedures, 
during a 3-month period (between March 23rd and June 
25th, 2018). In the local laboratory, APTT is performed 
using HemosIL SynthaSil (Instrumentation Laboratory, 
Bedford, USA). The local reference range is comprised 
between 0.89–1.30 in ratio, and between 25.1–36.5 in 
seconds, respectively. Whenever prolonged APTT results 
are observed, the abnormal data might then be investigated 
according to a tentative algorithm. Briefly, APTT results 
are combined with familiar history of bleeding (yes/no), 
personal history of bleeding (yes/no) and signs/symptoms 
of bleeding, eventually followed by results of additional 
hemostasis tests, including mixing test, LAC and clotting 
factor assays, as summarized in Figure 1. Regarding follow-
up testing, mixing test is performed according to the 
method described by Rosner et al. (14) using HemosIL 
SynthaSil (Instrumentation Laboratory, Bedford, USA; 
normalization defined for values <15%), “intrinsic pathway” 
clotting factors activity is measured by means of one-stage 
clotting assays using HemosIL SynthaSil (Instrumentation 
Laboratory, Bedford, USA) and HemosIL Factor deficient 
plasmas (Instrumentation Laboratory, Bedford, USA; local 
reference values: FVIII, 60–150%, FIX, 60–150%, FXI, 65–
120%, FXII, 70–130%), whilst LAC testing is carried out 
with silica APTT (Silica Clotting Time, Instrumentation 
Laboratory, Bedford, USA; reference values, <1.16 
normalized ratio) and dilute Russell viper venom time 
(dRVVT Screen and dRVVT Confirm, Instrumentation 
Laboratory, Bedford, USA reference values, <1.16 
normalized ratio), as for current recommendations (15). All 
tests are carried out using ACL TOP 500 (Instrumentation 
Laboratory, Bedford, USA) and are regularly validated by 
performance of internal quality control (IQC) procedures 
and participation to an External Quality Assessment 
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(EQA) scheme. Sensitivity and specificity of the tentative 
algorithm were calculated according to the final diagnosis 
(i.e., successful surgery and identification of bleeding or 
prothrombotic disorders). The statistical analysis was 
carried out using MedCalc 17.9 (MedCalc Software, 
Ostend, Belgium). 
Results
Overall, 1,433 patients underwent preoperative laboratory 
testing throughout the 3-month study period, 76 (5.3%) 
of whom were found to have a prolonged APTT value 
(i.e., >36.5 s). The remaining 1,357 (94.7%) patients 
underwent successful surgery, without further investigation. 
According to the algorithm (Figure 1), 55/76 (72.4%) of 
patients with prolonged APTT were excluded from further 
laboratory testing because they had already received a 
previous diagnosis explaining the prolongation or were 
taking anticoagulant drugs, so that they were considered 
not worthy enough of additional urgent investigations. In 
the remaining 21/76 (27.6%) patients, a mixing test was 
planned, since the prolongation of the APTT could not be 
otherwise explained. In 5/21 (23.8%) of these patients the 
mixing test was positive (i.e., no normalization), so that LAC 
testing was scheduled. In all these five patients the results of 
LAC testing was positive. In the remaining 16/21 (76.2%) 
patients, the mixing test was negative (i.e., normalization), 
so that clotting factors assays were scheduled. The results 
of these tests are shown in Figure 2. Briefly, 7 patients 
were finally diagnosed with FXII deficiency (FXII activity 
comprised between 29% and 68%), two patients with 
mild FXI deficiency (i.e., FXI activity of 47% and 51%, 
respectively), whilst 5 patients were found to have clinically 
insignificant low values of one or more clotting factors and 
2 patients had no identifiable explanation for the APTT 
prolongation. In one patient with FXII deficiency, a LAC 
positivity of borderline significance could also be detected. 
Notably, no significant correlation (Spearman’s test) could 
be observed between residual clotting factor activity in 
plasma and APTT (r =0.03; P=0.949) in the 9 patients with 
prolonged APTT due to either FXII or FXI deficiencies. 
Overall, the sensitivity and specificity of the preoperative 
algorithm for detecting clinically significant conditions (i.e., 
FXI deficiencies or LAC) were 1.00 (95% CI, 0.59–1.00) 
and 0.99 (95% CI, 0.98–0.99), respectively.
Discussion
A prolonged APTT may be caused by a number of clinically 
significant conditions, such as congenital or acquired 
clotting factors deficiencies or clotting factors inhibitors, 
but may also be due to clinically silent conditions, the most 
frequent of which is indeed FXII deficiency (8). Beside 
patients presenting with a positive familiar or personal 
history of bleeding, and for whom second-line testing (i.e., 
clotting factors assays) is virtually mandatory (16), the 
investigation of the remaining patients is still a matter of 
concern. 
Performance of mixing test is a cost-effective approach 
for obtaining rapid and clinically useful information in 
Figure 1 Tentative algorithm for investigating patients with 
unexpected prolongation of activated partial thromboplastin time 
(APTT), detected during preoperative laboratory testing. LAC, 
lupus anticoagulant.
Prolonged APTT
Patient known?
Anticoagulants?
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patients with prolonged APTT (17). Once preanalytical 
causes of prolongation have been ruled out (18), the 
normalization of this tests is suggestive for the presence of 
clotting factor deficiencies, whilst failure to normalize is 
highly suggestive for the presence of endogenous (i.e., anti-
factor antibodies, thus including inhibitors and LAC) or 
exogenous (i.e., heparin) inhibitors. A protocol (Figure 1) 
has hence been designed, exactly around this principle, in 
that the diagnostic strategy will be driven by the familiar or 
personal clinical history, by the presence of signs/symptoms 
of bleeding, and by performance of mixing test in patients 
in whom the APTT prolongation cannot be otherwise 
explained. Overall, mixing test was hence performed in 
21/1,433 (1.5%; i.e., in 27.6% of those with prolonged 
APTT) (Figure 2). Although this volume of tests will not 
pose a substantial economic and organization burden on the 
laboratory, the identification of two patients with modest 
FXI deficiency (i.e., FXI activity of 47% and 51%) carries 
important clinical consequences. Patients with FXI values 
>40% do not usually have enhanced risk of perioperative 
bleeding, but it has also been demonstrated that some of 
them may need replacement therapy before undergoing 
high-risk surgical procedures, especially involving organs 
with higher fibrinolytic potential (i.e., mouth, nasal 
cavity or prostate) (19). These patients, who are usually 
asymptomatic until subjected to procedures at higher risk 
of haemorrhage, would have not been recognized without 
performing a preoperative APTT. Interestingly, the lack of 
correlation observed between APTT and both FXII and 
FXI values attests that the extent of prolongation of this test 
may not be a reliable guidance for suspecting either the type 
or the severity of clotting factor deficiency.
Albeit the clinical usefulness of preoperative APTT 
for identifying patients at increased risk of perioperative 
bleeding has hence clearly emerged from our data, the 
identification of five additional asymptomatic patients 
with positive LAC testing is another valuable finding. 
There is now reliable evidence that patients with LAC 
or antiphospholipids antibodies have a significantly 
enhanced risk of postoperative thrombosis, especially those 
undergoing cardiac or vascular surgery (20,21). Specific 
prophylaxis and tailored postsurgical treatment has hence 
been advocated in these patients, since this approach may be 
effective to lower their otherwise increased thromboembolic 
risk (22). 
On the other hand, no clinically significant abnormalities 
could be detected in the remaining 14 patients undergoing 
mixing test (Figure 2). Although these may hence be 
theoretically regarded as “false positive” results, the 
overall diagnostic sensitivity and specificity of the local 
algorithm for identifying patients with clinically significant 
prolongation were both ≥0.99, thus inherently confirming 
its potential clinical usefulness. Interestingly, in 7 of these 
patients the final diagnosis was FXII deficiency, which 
has a well-known impact on APTT prolongation in vitro, 
but whose clinical significance is most likely meaningless, 
wherein no significant bleeding can be conventionally 
observed in patients with even homozygous deficiencies of 
this factor (23).
Conclusions
Taken together, the results of this study seemingly confirm 
previous suggestions that a preoperative algorithm 
1433 patients tested
Reason known?
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YES
(55/1,433; 3.8%)
No normalization
(5/1,433; 0.3%)
LAC TESTING FACTORS ASSAYS
Prolonged
(76/1433; 5.3%)
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(21/1,433; 1.5%)
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FXII deficiency
(7/1,433; 0.5%)
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(2/1,433; 0.1%)
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low values
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(5/1,433; 0.3%)
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Figure 2 Validation of local algorithm for investigating patients 
with unexpected prolongation of activated partial thromboplastin 
time (APTT), detected during preoperative laboratory testing. F, 
factor; LAC, lupus anticoagulant.
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including clinical (familial or personal history of bleeding) 
and laboratory data (results of APTT, mixing test, LAC 
and clotting factor assays) may be a reasonable and 
sustainable strategy for identifying patients at enhanced 
risk of perioperative bleeding or thrombosis (24,25). 
We also highlight that consideration should be made to 
include mixing test among the laboratory armamentarium 
of routine and urgent analyses, since it is a relatively easy 
and inexpensive test, which may provide rapid and valued 
clinical information for perioperative patient management.
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